Alvotech Completes $100m Private Placement
Second Round Adds $35m After $65m First Round In October
Executive Summary
Alvotech has completed a $100m private placement after concluding a second found of funding worth $35m. The move comes as the company prepares to commercialize its portfolio of biosimilars through a series of partnerships.
You may also be interested in...
Alvotech Value Rises Again As Portion Of Debt Is Wiped Away
Icelandic biosimilars specialist Alvotech has eased some of its liability to bondholders following a debt-to-equity conversion, at the same time as it improved terms and extended its maturity.
Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand
Cipla has expanded its partnership with Alvotech to cover the commercialization of four biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
Partnerships Provide Global Foundation For Alvotech
A network of marketing deals with key players across the globe has laid the foundations for Alvotech’s biosimilars to be marketed worldwide, the company’s founder and chairman tells Generics Bulletin in an exclusive interview.